Passage Bio, Inc. (NASDAQ:PASG) Q4 2022 Earnings Call Transcript

Will Chou: Sure. So let me take that one Mark. So our initial data from Cohort 1 is going to focus on safety and CSF progranulin level. So we plan to report progranulin levels at baseline and after 30 days in the CSF. What was the second part of your question?

Whitney Ijem: So I guess as it relates to CSF progranulin then what are — is there a target level that you’re aiming for? And are you expecting — or I guess what are your expectations given this is the first dose cohort relative to that potential target?

Will Chou: Sure, of course. So based on our preclinical data what we saw at this current dose level is, physiologic levels of CSF program. So our expectations would be to at least see physiologic levels of CSF program. I would like to say that, before we discussed the patient recruitment and because of all the patients we have who are identified at sites who are GRN positive, we are confident and looking forward to sharing data from the first cohort of patients in the second half of this year.

Whitney Ijem: Got it. And then, second part of the question I guess is, I believe there is targeting enrollment of three patients in this first cohort, correct me if I’m wrong. But is the expectation to provide data on a complete cohort, or will you provide data on if it ends up not being a complete cohort dose in the second half you’ll provide data on whatever patients you have treated?

Will Chou: We’ll be providing data on multiple patients from the first cohort. And we will be able to give more specific guidance to that later this year.

Whitney Ijem: Okay. Great. Thanks for taking my questions.

Operator: And I’m showing no further questions in the queue at this time. Ladies and gentlemen, thank you for participating in today’s conference. This does conclude your program. And you may now disconnect. Everyone have a great day.